EnFusion 3 callers
EnFusion 3 callers; bounded primary-source AMP candidate.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Model Capabilities & Hardware Requirements
Deployment facts recorded for EnFusion 3 callers. Fields the record does not carry are marked not recorded.
Evaluations and results
1 evaluation · 4 results. Different protocols are not a single leaderboard.
Protocol: EnFusion undiluted Seraseq duplicate benchmark · Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries
Sorted by Precision (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Precision | Recall | True positives (seraseq spike-in fusions, mean of duplicates) | Count (all fusion calls, mean of duplicates) |
|---|---|---|---|---|
| EnFusion 3 callersEvaluation | 90.3% | 100% | 14 | 15.5 |
All 4 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 14 True positives (seraseq spike-in fusions, mean of duplicates) count · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 15.5 Count (all fusion calls, mean of duplicates) count · unknown Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 90.3% Precision percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
| Configuration: EnFusion 3 callers | Protocol: EnFusion undiluted Seraseq duplicate benchmark Dataset: Undiluted Seraseq Fusion RNA control, duplicate libraries | 100% Recall percent · higher Uncertainty: Not yet extracted Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceConsensus ≥3 callers, with specified filtering and known fusion list rescue; Table 2 displays mean of duplicate undiluted experiments. Only 14 Seraseq fusions are positive; all others counted false positive. Comparators processed by same authors. Aggregation: Not reported Discovery of clinically relevant fusions in pediatric cancer · Table 2, EnFusion 3 callers row, corresponding column (JATS Tab2) |
Source checking is not independent reproduction. Release 2026-11-21-adc15377fab2.
Use this configuration
How it works, versions and access
Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-adc15377fab2 · Record review: source checked
1 source record and release history
- Discovery of clinically relevant fusions in pediatric cancer · Original source · Europe PMC fullTextXML retrieved 2026-10-07T12:25:20.810843+00:00
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID amp-oncology-rna-20261007-issue-11-config-enfusion-3-callers.
Related records
- system: EnFusion 3 callers evaluation
How to cite
EnFusion 3 callers. Rewire biological model benchmark database, release 2026-11-21-adc15377fab2. https://benchmarks.rewirebio.io/database/configuration/amp-oncology-rna-20261007-issue-11-config-enfusion-3-callers/
Release 2026-11-21-adc15377fab2. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence